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ABSTRACT
While in the last decade mRNA expression profiling
wasamongthemostpopularresearchareas,overthe
past years the study of non-coding RNAs, especially
microRNAs(miRNAs),hasgainedincreasinginterest.
For almost 900 known human miRNAs hundreds of
pretended targets are known. However, there is only
limited knowledge about putative systemic effects of
changes in the expression of miRNAs and their regu-
latory influence. We determined for each known
miRNA the biochemical pathways in the KEGG and
TRANSPATH database and the Gene Ontology
categories that are enriched with respect to its
target genes. We refer to these pathways and
categories as target pathways of the corresponding
miRNA. Investigating target pathways of miRNAs we
found a strong relation to disease-related regulatory
pathways,includingmitogen-activatedproteinkinase
(MAPK) signaling cascade, Transforming growth
factor (TGF)-beta signaling pathway or the p53
network.Performingasophisticatedanalysisofdiffer-
entially expressed genes of 13 cancer data sets
extracted from gene expression omnibus (GEO)
showed that targets of specific miRNAs were signifi-
cantly deregulated in these sets. The respective
miRNA target analysis is also a novel part of our gene
setanalysispipelineGeneTrail.Ourstudyrepresentsa
comprehensivetheoreticalanalysisoftherelationship
betweenmiRNAsandtheirpredictedtargetpathways.
Our target pathways analysis provides a
‘miRNA-target pathway’ dictionary, which enables re-
searchers to identify target pathways of differentially
regulated miRNAs.
INTRODUCTION
Despite recent advances in sequencing methodology,
microarray expression proﬁling is still a major technique
for studying natural and pathogenic biochemical
processes. While in the past decade the analysis of
coding RNA molecules, mostly messenger RNAs
(mRNAs) were in the focus of research, the relevance of
non-coding RNAs has not been realized as of recent years.
Especially microRNAs (miRNAs) are of increased
interest. Currently, 922 human miRNAs are annotated
in the Sanger miRBase (1–3) version 14 and the amount
of miRNAs is steadily increasing.
These endogenous non-coding small RNAs usually of
length 19–23nt are known to regulate the translation of
the coding mRNAs in a sequence-speciﬁc manner.
miRNAs seem to be involved in almost all biological
processes, including cellular development, diﬀerentiation,
proliferation or apoptosis (4,5). Evidently, these molecules
also play an important role in cancer, as recently reviewed
by Drakaki et al. (6). A variety of studies describe that
miRNAs can function either on tumor suppressor genes or
on oncogenes and thus acting as major regulators of gene
expression. While they were so far considered to be
negative regulators, recent studies impressively demon-
strate that miRNAs can also have positive eﬀects on
gene expression (7).
Similar to transcription factors, miRNAs can bind
perfectly or imperfectly in the 30 untranslated region
(UTR) of target genes and thereby regulate their expres-
sion. For gene regulation via miRNAs, mainly three
diﬀerent mechanisms are known, including (i) translation
repression, (ii) direct mRNA degradation and (iii)
miRNA-mediated mRNA decay (8). Mostly, miRNAs
bind with imperfect complementarity to their targeted
mRNAs and thereby guide mRNA translation
repression. They interact with targeted mRNAs primarily
through the so-called seed, a 6–8nt long region at their
50-end. This seed is known to be highly conserved in
miRNA families across diﬀerent species (9).
There is a steady progress in detecting the biological
functions of miRNAs, with the target identiﬁcation
mediating the respective functions as the most challenging
task. One commonly applied approach is to measure the
reduction in target mRNA levels caused by an
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(10). Potential targets are typically validated by using
luciferase sensors containing the target 30-UTR.
In addition to experimental approaches, a variety of
computer-aided prediction algorithms have been
developed (11–14). These algorithms are trained by well-
known miRNA–mRNA interaction rules gained from
microarray data in order to identify novel miRNA
targets. Among the most popular algorithms is miRanda
that is freely available at http://www.microrna.org (11).
One of the most comprehensive resources for miRNA
targets is MicroCosm, a web resource developed by the
Wellcome Trust Sanger Institute and now hosted by the
European Bioinformatics Institute (EBI) containing com-
putationally predicted targets for microRNAs across
many species. The targets of MicroCosm have been pre-
dicted with the miRanda algorithm. Beside miRanda,
several other tools for target prediction are available.
For a review on such tools see Bartel (15). While
TargetScan (16), PicTar, (17) or PITA (18) use conserva-
tion information, other tools as RNA22 (19) do not rely
on such data. The analyses in this work is based on
MicroCosm since this algorithm acknowledges comple-
mentarity at the 50-end of the microRNA, where a
rather strict complementarity is required, excludes
non-stable conformations by using the Vienna RNA
folding approach and, in addition, checks whether the
site is conserved in orthologous transcripts from other
species. However, most of the proposed methods suﬀer
from either high false positive or false negative rates
thus showing insuﬃcient speciﬁcity or sensitivity. One
reason for the low speciﬁcity (and sensitivity) may be the
lack of negative examples or miRNA-target pairs that are
required for a suitable training of the classiﬁcators. To
improve the false discovery rate, Bandyopadhyay and
Mitra identiﬁed 300 negative examples using expression
proﬁling of miRNAs and mRNAs and miRNA–mRNA
structural interactions together with seed site conservation
(20). Based on these data, their ‘TargetMiner’, which relies
on a support vector machine, achieved a speciﬁcity of
69% and and a sensitivity of 67.8%. Recently, the
challenges related to miRNA target prediction have
been summarized by Barbato et al. in their work
‘Computational Challenges in miRNA Target
Predictions: To Be or Not to Be a True Target?’ (21).
To further improve our understanding of the mode of
action of miRNAs and their function, gene set analysis
based approaches can be used. Most recently, the group
of Hatzigeorgiou proposed two approaches, DIANA-
microT (22) and DIANA-mirPath (23). The DIANA-
mirPath software performs an enrichment analysis of
multiple miRNA target genes comparing each set of
miRNA targets to all known KEGG pathways (24,25)
and thus is a valuable tool for elucidating targets that
are aﬀected by deregulated miRNAs.
The increasing amount of mRNA and miRNA expres-
sion data induces a strong demand for computer-aided
tools that facilitate the integrative analysis of these data.
Among the most popular tools developed for this purpose
is ‘microRNA and mRNA Integrated Analysis’ developed
by Nam et al. (26) that interprets miRNA and mRNA
data in the context of gene ontologies and biochemical
pathways.
Our study aims at an improved understanding of
miRNA and mRNA relations by addressing three issues.
First, as a sequel of the study by Hatzigeorgiou et al.,w e
carry out a comprehensive gene set analysis of the miRNA
target sets by considering not only KEGG pathways
but also TRANSPATH networks (27), TRANSFAC
(28) transcription factors and Gene Ontologies (GO)
categories (29). Second, we perform a network analysis
of all target genes of all miRNAs. Third, we propose a
tool for screening diﬀerentially expressed mRNAs for en-
richment of speciﬁc miRNA targets and apply this tool to
expression proﬁles of 13 data sets of diﬀerent cancer types
containing together over 1.000 microarrays. Our tool is
freely accessible as part of our comprehensive gene set
analysis pipeline GeneTrail (30,31).
Taken together, our study contributes to an improved
understanding of the interactions between miRNAs and
putative target genes and also provides a comprehensive
‘miRNA-target pathway’ dictionary. This dictionary
enables researchers to readily identify target pathways of
diﬀerentially regulated miRNAs. The study also provides
further evidence that miRNAs are key players in the regu-
lation of oncogenic processes.
MATERIAL AND METHODS
Information resources and databases
As a resource for predicted miRNA targets, we down-
loaded the MicroCosm Targets (‘miRBase Targets
Release Version v5’) (1–3) from the EBI. This information
was integrated in our gene set analysis tool GeneTrail to
have direct access to its diﬀerent statistical evaluation
methods and predeﬁned biological categories as described
in (30,32). For the network analysis, we imported the in-
formation for Homo sapiens from KEGG (24,25) into our
biochemical network database (BNDB) (33) and imple-
mented a graph data structure based on the boost graph
library (34) for eﬃcient usage of the network topology.
Network analysis
The regulatory network is modeled as a directed graph
G=(V, E), where the vertices (nodes) V={v1,...,vn}
represent proteins, protein families, protein complexes or
other participants and the directed edges e=(vi,vj)2E
represent reactions or interactions between these partici-
pants. For analyzing the connectivity of miRNA targets in
detail, we computed the average distance between all
targets of each miRNA. Since our considered regulatory
network is directed, the distance of two nodes dist(vi,vj)i s
not necessarily equal to dist(vj,vi). Therefore, we chose for
each pair (vi,vj) the minimum of these distances for the
computation of the average distance. If there exists no
path between two nodes, the distance was set to the
diameter of the complete regulatory network to penalize
the absence of a path. The sum of the pair distances is
ﬁnally divided by the number of pairs considered. To
estimate if the average distance of the m targets of one
miRNA is signiﬁcant, we carried out 1000 permutation
Nucleic Acids Research, 2010,Vol.38, No. 13 4477tests for each target set size m. To this end, we randomly
selected m nodes from the complete network and
calculated the average distance for the random node set.
Finally, the overall distribution of the average distances of
the randomly selected nodes and the miRNA targets was
compared by performing an unpaired two-tailed t-test.
Gene set enrichment analysis
For computing the statistical signiﬁcance of an arbitrary
biological category C given a sorted list of genes of size n,
we apply the so-called unweighted ‘Gene Set Enrichment
Analysis’ (GSEA) as proposed by Lamb et al. (35). Using
a Kolmogorov–Smirnov-like test that computes whether
the genes in C are equally distributed in the sorted list or
accumulate on top or on bottom of the list, we determine
if the considered category is signiﬁcantly enriched or
depleted. If l genes of the sorted list belong to C,w e
compute the running sum by processing the input list
from top to bottom adding n l to the running sum if
the considered gene belongs to C or subtracting l other-
wise. The value of interest is the running sum’s maximal
deviation from zero, denoted as RSC. The signiﬁcance
value of the score RSC can be calculated by a dynamic
programming algorithm that computes the exact number
of possible running sum statistics with higher deviation
than RSC. For details on the implemented algorithm we
refer to (32).
RESULTS AND DISCUSSION
The results presented in this work rely on predicted
miRNA targets for Homo sapiens as annotated by
MicroCosm that are based on the miRanda algorithm
(11). The possible targets of each miRNA are tagged
with a signiﬁcance value, the lower this value is the
higher the chance that the respective gene is actually
targeted by the respective miRNA. In order to balance
sensitivity versus speciﬁcity, we considered three signiﬁ-
cance levels (a-levels): 0.01, 0.001 and 0.0001. Notably,
the highest speciﬁcity (fewest false positives) are reached
at the lowest threshold value.
Furthermore, we provide (i) a comprehensive gene set
analysis of the miRNA target sets, (ii) a network analysis
of all target genes of all miRNAs and (iii) Gene Set
Enrichment analyses of 13 cancer data sets, where we
study the enrichment of miRNA targets in sets of genes
(mRNA) that are diﬀerentially expressed in the corres-
ponding tumor biopsies.
miRNA target enrichment analysis
In order to detect target pathways of miRNAs, we carried
out standard over-representation analysis as described in
(30). In brief, for each of the human miRNAs in the
Sanger miRBase (1,2,4) we extracted all targets with sig-
niﬁcance value below a given a-level t. The resulting  800
gene sets for Homo sapiens were separately evaluated
using GeneTrail (30) analyzing about 13000 biological
pathways and categories including KEGG pathways,
TRANSPATH pathways, Gene Ontology terms and
others using all human genes as background set.
The resulting signiﬁcance values have been adjusted by
applying the Benjamini–Hochberg approach (36,37).
As expected, the number of overall target genes drops
from 16200 over 13200 to 8500 for the target signiﬁcance
levels of 0.01, 0.001 and 0.0001, respectively. The follow-
ing detailed analysis has been carried out with the
most sensitive signiﬁcance threshold of 0.0001. The
respective tables for all thresholds can be found in
the Supplementary Data.
Of 13160 screened biological categories, 1766 are sig-
niﬁcant for at least a single miRNA. The highest number
of hits are achieved by the categories ‘Metabolic
Pathways’ (30), ‘Cell Cycle’ (23) and ‘Pathways in
cancer’ (20) followed by a long list of disease relevant
pathways including TGF-beta and MAPK signaling
cascade (see also Table 1, categories which are signiﬁcant
for >10 miRNA target sets).
For target sets of 254 miRNAs, at least one signiﬁcant
category has been found. On average each miRNA has
ﬁve signiﬁcant categories. The miRNAs with the highest
number of signiﬁcant categories was miR-202 (90)
followed by miR-101 (65). A list of miRNAs whose
targets are enriched in >40 signiﬁcant categories is
provided in Table 2.
To improve our understanding of the putative pathways
or biological categories that miRNAs may regulate or in-
ﬂuence, we carried out a clustering approach. First, we
removed miRNAs with <5 signiﬁcant categories and
categories that are enriched for <5 miRNA target sets.
The clustering is based on a binary matrix that describes
which categories (rows) are enriched with respect to the
corresponding miRNA target sets (columns), i.e. the
matrix contains a 1 at position (i,j) if the targets of
Table 1. Categories that are most frequently enriched with miRNA
target gene sets
Category Number of
signiﬁcant
miRNA target
gene sets
Metabolic pathways 30
Cell cycle 23
Pathways in cancer 22
Focal adhesion 15
TGF-beta signaling pathway 13
Fatty acid metabolism 13
Catalytic activity 12
Cellular ketone metabolic process 12
ECM-receptor interaction 11
Fc epsilon RI signaling pathway 11
Organic acid metabolic process 11
Carboxylic acid metabolic process 11
MAPK signaling pathway 11
Substrate-speciﬁc transporter activity 11
Substrate-speciﬁc transmembrane transporter activity 11
Oxoacid metabolic process 11
Transporter activity 10
E2F network 10
Valine, leucine and isoleucine degradation 10
p53 signaling pathway 10
Colorectal cancer 10
Toll-like receptor signaling pathway 10
4478 Nucleic Acids Research, 2010,Vol.38, No. 13miRNA j are enriched in category i and a 0 otherwise.
Based on this matrix, we carried out a hierarchical clus-
tering of miRNAs and categories separately. In more
detail, we applied bottom-up hierarchical clustering
using the Euclidian distance for measuring the distances
between pairs of column and row vectors. The result
of this clustering is shown in Figure 1. In the lower left
corner of the heatmap, a cluster containing the let-7
family can be detected. These miRNAs seem to con-
trol, among others, categories as ‘transporter activity’,
‘RNA interference’, ‘macrolide binding’ or ‘drug
binding’. The second cluster in the lower left corner
contains miRNAs hsa-miR-525-3p, hsa-miR-524-3p,
hsa-miR-506, hsa-miR-614, hsa-miR-920, hsa-miR-124,
hsa-miR-376a and hsa-miR-376b that control metabolic
pathways.
We also addressed the question how speciﬁc the
detected pathways or categories are and whether there
are pathways or categories that are triggered by
miRNAs in general. To this end, we set up three lists,
containing genes that are targets of at least one miRNA
at a target threshold level of 0.01, 0.001 and 0.0001. These
lists containing 16.217, 13.168 and 8.508 genes have been
processed using GeneTrail.
For the most unspeciﬁc miRNA target threshold of 0.01
no signiﬁcant KEGG pathways have been detected,
indicating that this threshold may lead to too many false
positive miRNA–mRNA target relations. In contrast, the
target threshold values of 0.001 and 0.0001 showed
increased numbers of pathways and additionally entailed
a signiﬁcant overlap between both sets. For 0.001, we
detected 12 putative target pathways while for 0.0001, 10
such pathways have been detected. Of these, ﬁve pathways
were signiﬁcant for both sets including ‘Basal cell carcin-
oma’, ‘ECM-receptor interaction’, ‘MAPK signaling
pathway’, ‘Metabolic pathways’, and ‘Pathways in
cancer’. A summary of all pathways and all threshold
values is presented in Table 3. The four columns of this
table describe the pathway name followed by the three
diﬀerent signiﬁcance values used for the target prediction.
The signiﬁcance value for the gene set enrichment analysis
has been hold constantly at 0.05 for all three analyses.
Remarkably, this table shows that for the most unspeciﬁc
miRNA target sets (P<0.01), no signiﬁcant pathways
were detected while for the more speciﬁc miRNA target
sets (P<0.001 and P<0.0001) several signiﬁcant
pathways were found.
miRNA target network analysis
For the network analysis of miRNAs, we retrieved the
KEGG regulatory network for Homo sapiens from our
BNDB (33). The resulting graph contains 1679 nodes
and 2509 edges in total. Since not all predicted targets of
the available 851 human miRNAs could be mapped onto
the regulatory network, we removed those miRNAs where
<10% of the targets could be mapped or the overall
number of mapped targets was <3, resulting in 695 re-
maining miRNAs. In the following analyses, we used the
threshold value of 0.001 for the miRNA targets.
For the considered miRNAs, we wanted to investigate if
the average distance between pairs of targets for the dif-
ferent miRNAs is signiﬁcantly lower in comparison to
randomly selected nodes from the complete network. To
this end, we computed for each pair of targets or
randomly selected nodes their distance. If no path be-
tween the considered nodes existed, we added the
diameter of the complete graph as penalty term. The
distribution of the average distances of randomly
selected nodes against the average distances of the
miRNA targets is shown in Figure 2. For testing the sig-
niﬁcance, we performed an unpaired two-tailed t-test,
which yielded a P-value <10
 9 conﬁrming that miRNA
target pairs have a lower average distance than randomly
selected nodes.
Furthermore, we analyzed the coverage of all miRNA
targets and the complete regulatory network considering
only such nodes that are proteins (not protein families or
complexes). When regarding the union of the targets of
each of the 695 miRNAs that can be mapped to proteins
in the network, we reach a coverage of the regulatory
network of 640/825 (78%). If we take the number of all
human genes having an amino acid sequence as reference
set (25673), we would expect to ﬁnd about 414 proteins
mapped on the network instead of 640, if we choose 12885
miRNA targets from the reference set coding for proteins.
The hypergeometric distribution test yields a P-value of
<10
 60 for obtaining such a coverage per chance. This
ﬁnding signiﬁcantly points out the crucial role these
miRNAs play in the regulation of biochemical processes
and indicates that the regulation takes place on basis of
balance and interplay of concentrations of miRNAs rather
than by regulating some few important targets or hubs in
the network.
Table 2. miRNAs with highest number of signiﬁcant categories
miRNA Number of signiﬁcant categories
Gene
Ontology
KEGG TRANSFAC TRANSPATH Total
hsa-miR-202 89 1 0 0 90
hsa-miR-101 64 0 0 1 65
hsa-miR-613 55 6 0 0 61
hsa-miR-936 58 0 0 0 58
hsa-miR-196a 54 0 2 0 56
hsa-miR-1 53 1 1 0 55
hsa-let-7f 49 0 1 0 50
hsa-miR-302b* 48 1 0 0 49
hsa-miR-23b 47 0 1 0 48
hsa-miR-212 43 4 0 0 47
hsa-miR-23a 47 0 0 0 47
hsa-miR-196b 44 0 2 0 46
hsa-miR-29c 40 5 1 0 46
hsa-miR-191 45 1 0 0 46
hsa-miR-181c* 45 0 0 0 45
hsa-let-7a 44 0 1 0 45
hsa-miR-801 43 0 0 0 43
hsa-miR-29a 37 3 1 0 41
hsa-miR-199b-5p 39 1 0 0 40
hsa-miR-29b 36 3 1 0 40
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In this section, we analyze whether the deregulation of
genes in cancer could be caused by miRNAs. More
exactly, we investigated if genes that are deregulated in
cancer are statistically signiﬁcant enriched with targets
of certain miRNAs for a sophisticated set of diﬀerent
cancer entities and a total of over 1.000 microarray experi-
ments. These arrays, extracted from the gene expression
omnibus (GEO) (38), are measured using the same
platform, GPL96. Here, a large control cohort is also
available, the data set GDS596 (39) containing 158
samples from 79 physiologically normal tissues obtained
from various sources.
We considered three slightly diﬀerent scenarios. For
most cancer data sets, we compared diseased to samples
of the control data set GDS596. This has been done in 10
data sets. For two data sets where matched controls have
been provided, we compared diseased samples with the
matched controls. Finally, we also investigated one data
set, where paired controls are available. In this case,
healthy and diseased lung tissue of lung cancer patients
were available. The three blocks in Table 4 show the
results for the three diﬀerent scenarios.
For all 13 data sets, we carried out the following
analysis procedure by using GeneTrailExpress (31).
First, we computed for each gene on the microarray the
fold quotient of medians in the control and diseased
group. The resulting list of genes sorted by the fold
Figure 1. This heatmap presents signiﬁcant miRNA to putative pathway or category correspondences. The heatmap has a red spot at position (i, j)i f
the targets of an miRNA j are signiﬁcantly enriched in category i. In the bottom left corner, a cluster containing the let-7 family can be detected.
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list, we carried out analyses for detecting miRNAs whose
targets are signiﬁcantly up- or downregulated using
standard GSEA. For the analysis of all 13 data sets, we
set the target threshold to 0.001. In addition, we also
investigated the inﬂuence of varying this threshold
between 0.01 and 0.0001 for two data sets (glioma and
lung cancer) exemplarily. The reported ﬁndings are
ﬁnally compared in order to identify miRNAs that are
either speciﬁc for certain cancer types or common to
certain groups of cancer types.
All results are summarized in Table 4. Because of space
restrictions we only discuss the most interesting results.
The complete result set is available as supplementary
Data of this article and will be integrated in a comprehen-
sive database.
Pheochromocytoma. We extracted the data set GDS2113
containing 75 tumors and compared with to the control
set GDS596. Here, we found 29 miRNAs, 24 over- and 5
underrepresented. The most signiﬁcant miRNAs were
hsa-miR-615-5p, hsa-miR-615-3p and hsa-miR-127-3,
which are related to a manifold of cancer entities [breast
neoplasms, colonic neoplasms, prostatic neoplasms, acute
myeloid leukemia, ovarian cancer and others; (40)].
High-grade glioma. For high-grade gliomas (WHO grade
III and IV astrocytomas), we considered two data sets of
the GEO, GDS1975 and GDS1815, that have been
analyzed separately.
We extracted the data set GDS1975 containing 85
tumors for comparison against the control set GDS596.
Here, we found 115 miRNAs, 74 over- and 41
underrepresented. The most signiﬁcant miRNAs were
hsa-miR-101, hsa-miR-200b and hsa-miR-200c.
For the data set GDS1815 that contains 100 samples,
we carried out the same analysis. Here, we detected by far
more signiﬁcant miRNAs, 168 of which 108 are over and
60 under represented. In addition, we compared the two
sets of signiﬁcant miRNAs. The ﬁrst set contained 115
miRNAs, the second set 168 miRNAs. The overlap
between both sets was 103, i.e. of the 115 miRNAs
detected for the smaller set, 90% were also signiﬁcant
for the independent second set.
For the larger data set containing 100 samples, we also
investigated the inﬂuence of the miRNA–mRNA target
threshold. For the target gene thresholds of 0.01, 0.001
and 0.0001, 388 (205 up, 183 down), 168 (108 up, 60
down) and 62 (53 up, 9 down) genes have been identiﬁed.
To reveal the similarity between the three target gene
threshold sets, we produced a three-way Venn diagram,
which is shown in Figure 3. This diagram outlines that,
e.g. the 62 signiﬁcant miRNAs for threshold 0.0001 split
in the following four groups: (i) six are signiﬁcant only for
this threshold, (ii) three are also contained in the set for
threshold 0.001, (iii) six are also contained in the set
for threshold 0.01 and (iv) the majority of 47 miRNAs
is signiﬁcant for all three thresholds.
The three miRNAs with highest signiﬁcance values
included hsa-miR-1, miR-200b and miR-144. These
miRNAs are known to be deregulated in various human
neoplasm’s (40). Looking speciﬁcally at miRNAs known
to be related to glioma tumors, we ﬁnd several occurrences
among the signiﬁcant miRNAs in the analyzed data sets,
including hsa-miR-181a and hsa-miR-181b. However,
some other popular miRNAs connected to glioma are
not detected to be signiﬁcant in our study, including
hsa-miR-221 and hsa-miR-222.
Non-autologous lung cancer samples. For this analysis, we
considered the data sets GDS2771 containing lung cancer
samples and controls and the data set GDS2373
Figure 2. Comparison of the distributions of the average distances
between randomly selected nodes on the left hand side and the
miRNA targets on the right hand side. The y-axis of this back-to-back
histogram presents the distance between nodes and the x-axis shows
how many percent of random node pairs and of miRNA targets have
this distance. The distribution of the miRNA targets is slightly shifted
toward smaller distances.
Table 3. KEGG pathways targeted by all miRNAs for diﬀerent
thresholds
Pathway 0.01 0.001 0.0001
ABC transporters – 0.0362 –
Aminoacyl-tRNA biosynthesis – – 0.0050
Basal cell carcinoma – 0.0154 0.0250
Complement and coagulation cascades – 0.0447 –
ECM-receptor interaction – 0.0447 0.0056
Epithelial cell signaling in Helicobacter
pylori infection
– 0.0495 –
Focal adhesion – – 0.0090
Glycine, serine and threonine metabolism – 0.0154 –
Lysosome – 0.0362 –
MAPK signaling pathway – 0.0018 0.0103
Metabolic pathways – 0.0119 0.0173
p53 signaling pathway – – 0.0420
Pathways in cancer – 0.0236 0.0269
Purine metabolism – – 0.0003
Steroid biosynthesis – 0.0447 –
Toll-like receptor signaling pathway – 0.0109 –
TGF-beta signaling pathway – – 0.0239
The values in the cells of the table correspond to the False Discovery
Rate (FDR) adjusted P-values computed for the pathway. –=not
signiﬁcant.
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to our standard control set GDS596. As Table 4 [lung
cancer (I) and lung cancer (II)] shows, we detected 130
and 292 miRNAs, respectively. Computing the overlap
between both sets, we found 101 miRNAs (77% of set
lung cancer II) to be consistent between both sets. Many
of these 101T miRNAs could be related to lung cancer
according to secondary literature (40), including
hsa-miR-181c, hsa-miR-18a, hsa-miR-19a, hsa-miR-203,
hsa-miR-210, hsa-miR-30b, hsa-miR-30d and hsa-
miR-30e. Similar to the results for glioma presented in
the previous section, we do not detect some miRNAs
to be signiﬁcant for lung cancer that are described to
be lung cancer related, including several members of the
let-7 family (e.g. hsa-let-7b, hsa-let-7c, hsa-let-7d and
hsa-let-7e) or hsa-miR-17.
Autologous lung cancer samples. As described above, we
extracted expression proﬁles of squamous lung cancer
biopsy specimens and paired normal specimens from 5
diﬀerent patients [GDS1312, (41)] from the GEO (38).
For this data set, a standard GSEA has already revealed
a manifold of deregulated pathways, including core regu-
latory pathways as the cell cycle (31).
The GDS1312 data set contains 10 samples, 5 normal
lung tissue expression proﬁles and 5 proﬁles of cancer
patients. Here, we considered targets with thresholds of
0.01, 0.001 and 0.0001 separately.
For the threshold value of 0.01 we detected 44 miRNAs
to be signiﬁcant. For 42 of these miRNAs, the targets were
signiﬁcantly upregulated in tumor tissue and for two
downregulated. Most of these miRNAs have been linked
to cancer in the literature, e.g. the most signiﬁcant miRNA
of these, hsa-miR-146b, is known to be downregulated in
lung cancer (42). For the miRNA target threshold of
0.001, we detected no signiﬁcant miRNAs (see Table 4),
while for the threshold of 0.0001 we detected the three
miRNAs miR-29a, miR-29b and miR-29c as signiﬁcant.
Notably, these miRNAs are also known to be
downregulated in lung cancer [miRNAs miR-29a
(43,44), miR-29b (42–44), miR-29c (43,44)). In addition,
we carried out a blood screening of healthy individuals
and lung cancer patients as described by Keller et al.
(45) using the Geniom RT Analyzer (febit biomed
gmbh, Heidelberg, Germany) and found these miRNAs
at least four times downregulated compared with the
control. For the most down-regulated miRNA, miR-29c,
the target network is presented in Figure 4 and the signiﬁ-
cant categories for its target genes are listed in Table 5.
If we now go back to our primary analysis of target
pathways presented in ‘miRNA target enrichment
analysis’ section 3.1, we detected for miRNAs miR-29b
and miR-29c the KEGG pathway ‘Small cell lung
cancer’ to be enriched with targets of these miRNAs.
This means that we can ﬁnd the predicted target
pathway directly in the expression data providing
evidence for the performance of the target pathway
prediction.
Clustering of data sets. Finally, we compared the diﬀerent
miRNA data sets identiﬁed with considered cancer
entities. To minimize a potential bias due to the usage of
diﬀerent control sets, we only used the 10 data sets with
the same control set, GDS596. Analyzing these 10 data
sets we found that the majority of miRNAs were rather
speciﬁc. In more detail, 30.5% were signiﬁcant for only
one data set, 17.1% were signiﬁcant for two data sets and
9.6% were signiﬁcant for three data sets. However, some
Table 4. Overview of cancer miRNAs
Entity # samples
cancer
# samples
controls
# signiﬁcant # over
represented
# under
represented
Pheochromocytoma 75 158 29 24 5
Glioma (I) 85 158 115 74 41
Glioma (II) 100 158 168 108 60
Breast 49 158 1 0 1
Myeloma (I) 50 158 68 57 11
Sarcoma 40 158 78 74 4
Acute myeloid leukemia (AML) 43 158 17 17 0
Color. adenoc. 37 158 90 64 26
Prostate cancer 22 158 92 88 4
Lung cancer (I) 129 158 130 96 34
Malignant pleural mesothelioma (MPM) 44 10 32 28 4
Lung cancer (II) 97 90 292 157 135
Lung cancer (III) 5 5 0 0 0
Figure 3. Three-way Venn diagram for the three glioma data sets
computed for the miRNA target thresholds 0.01, 0.001 and 0.0001.
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including hsa-miR-548a-3p (8 of 10 sets), hsa-miR-200b,
hsa-miR-200c, hsa-miR-1, hsa-miR-548c-3p, hsa-let-7f-2*,
hsa-miR-548a-5p, hsa-miR-590-3p, hsa-miR-548d-3p
and hsa-miR-548b-5p (all in 7 of 10 data sets). Looking
into the literature, we ﬁnd that, especially for miRNA
200b and 200c, a manifold of deregulations in diﬀerent
cancer entities is known [Cholangiocarcinoma, Colonic
Neoplasms, Thyroid Neoplasms, Breast Neoplasms,
Melanoma, Pancreatic Neoplasms, Adrenocortical
Carcinoma, Ovarian Neoplasms, Meningioma (40)].
Looking back to the target pathways of these miRNAs,
we ﬁnd among other categories diﬀerent metabolic and
regulatory pathways, for miR-548a-3p e.g. the Cell cycle,
Nucleotide excision repair, Aurora-B cell cycle regulation
and some transcription factors [T00874 (MLTF) and
T02338 (SP-3)]. The cell cycle is also signiﬁcant for
hsa-let-7f-2* and hsa-miR-548a-5p. Especially miR-200b
that is known to be deregulated in cancers has also
relevant target pathways, including basal transcription
factors, focal adhesion, TGF-beta signaling pathway,
c-Jun N-terminal kinase pathway, stress-associated
pathways, the FBJ osteosarcoma oncogene, anatomical
structure formation and cellular component assembly.
As for the target pathway analysis, we again carried out
a hierarchical clustering using the binary matrix where
each row represents a miRNA and each column a data
set. A matrix entry equals ‘1’ if the respective miRNA has
been detected for the corresponding data set, otherwise the
entry equals ‘0’. As the cluster dendrogram in Figure 5
shows, the two independently measured glioma data sets
cluster well together in the middle of the dendrogram. On
the left of this dendrogram, the entities with smaller sets of
signiﬁcant miRNAs cluster together, where the overlap
between the respective sets is comparably small and the
miRNAs are rather speciﬁc. On the right side of the den-
drogram, prostate cancer (showing 92 miRNAs) and soft
tissue sarcoma samples (showing 78 miRNAs) cluster
together. Remarkably, the sarcoma data set GDS1209
contains a mixture of gastrointestinal stromal sarcoma,
leiomyosarcoma, dediﬀerentiated liposarcoma, pleo-
morphic liposarcoma, malignant ﬁbrous histiocytoma
Figure 4. This ﬁgure presents the target network of the miRNA hsa-miR-29c. The subgraph consists of the nodes of the shortest paths between the
miRNA targets. The targets of the miRNA are colored in blue.
Nucleic Acids Research, 2010,Vol.38, No. 13 4483and synovial sarcoma samples. Both data sets, the
prostate and sarcoma set shown an overlap of 57
miRNAs.
CONCLUSION
Our computational analysis deepens the understanding of
miRNAs and their putative targets in biochemical
networks. We provide a comprehensive ‘dictionary’ of
miRNAs to possible target pathways that may be
regulated by these miRNAs. This dictionary enables re-
searchers to look up the target pathways of diﬀerentially
regulated miRNAs that can be used, e.g. for functional
studies. As an additional key result, our study also
provides further evidence that miRNAs are key players
in the regulation of oncogenic processes by interpreting
the results of 13 cancer microarray data sets. Thus, our
results also provide evidence that an integrative screening
of miRNAs and mRNAs can contribute to an improved
understanding of human diseases, ﬁnally furthering
disease diagnosis, prognosis and monitoring.
Table 5. Overview of the signiﬁcant categories for the target genes of miR-29c for a threshold value of 0.0001
Gene Ontology KEGG TRANSFAC
Collagen ECM-receptor interaction T09836 (hsa-miR-29c)
Extracellular matrix part Focal adhesion
Proteinaceous extracellular matrix Primary immunodeﬁciency
Extracellular matrix Small cell lung cancer
Extracellular matrix structural constituent Lysine degradation
Structural molecule activity
Anchoring collagen
Extracellular region part
Basement membrane
Collagen type IV
Sheet-forming collagen
Fibrillar collagen
Extracellular region
Extracellular matrix organization
Membrane part
Intrinsic to membrane
Membrane
Integral to membrane
Chromatin
Microﬁbril
Protein binding, bridging
Localization
FACIT collagen
Collagen ﬁbril organization
Androgen receptor binding
Cell adhesion
Biological adhesion
Fibril
Lysine N-methyltransferase activity
Protein-lysine N-methyltransferase activity
Histone-lysine N-methyltransferase activity
Extracellular structure organization
S-adenosylmethionine-dependent methyltransferase activity
Nuclear chromatin
Nuclear hormone receptor binding
Androgen receptor signaling pathway
Steroid hormone receptor binding
Histone methyltransferase activity
Hormone receptor binding
Protein methyltransferase activity
Figure 5. Dendrogram of signiﬁcant miRNAs. The dendrogram shows
the similarity of diﬀerent miRNA cancer sets. The two independently
measured glioma data sets cluster well together in the middle of the
dendrogram.
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